Today is Monday, January 2, 2023, at 20:12 in the evening. There is a big news. Let me tell you first that the XBB strain has been detected in Shanghai. This strain has infected large areas in Europe and the United States. Although the official stated that most of these cases are imported cases from abroad and are under closed-loop independent management, so they have not caused large-scale local transmission of the BQ.1 family and the XBB family, but it will inevitably worry the people. You can't stand it even if you have been exposed to the sun once. It would be even more terrible if you get infected again. Everyone should protect themselves and don't go out if nothing happens. Just now, I learned three more pieces of news, all of which are related to the stock market. I will quickly explain them to you. We still follow the old rules. New friends should add a follow in case they get lost. Old friends should continue to like and support. The first battle of the new year, how to go about Chinese stock market ? The official interpretation begins below:
News 1: The central bank stated that starting from January 3, 2023, the trading hours of the inter-bank foreign exchange market will be extended to 3:00 Beijing time the next day, the central parity rate of the RMB exchange rate and its floating range, market maker quotations and other market management systems will be extended accordingly. The release times of the central parity rate of the RMB exchange rate announced by the China Foreign Exchange Trading Center at 9:15 Beijing time and the closing price of the RMB against the US dollar spot and at 16:30 Beijing time remain unchanged.
First of all, extending the foreign exchange trading hours will help investors make decisions and promote the effective flow of funds. Secondly, affected by this news, the RMB exchange rate rose again. It has now fallen below 7 and stabilized above 6.9. Next, if the RMB exchange rate continues to strengthen, it will be hugely attractive to foreign capital. According to previous trends, if foreign capital flows in, the performance of the stock market will not be bad.
News 2: In order to further regulate the reduction of shares of controlling shareholders of listed companies on the Beijing Stock Exchange, shareholders holding more than 25% of shares, actual controllers and directors, supervisors, senior managers and other "key minorities", and protect investors. Legitimate rights and interests, Beijing Stock Exchange In accordance with the "Measures for the Continuing Supervision of Listed Companies on the Beijing Stock Exchange (Trial)" and the "Beijing Stock Exchange Stock Listing Rules (Trial)", and on the basis of regulatory practice and market suggestions, the Beijing Stock Exchange formulated the "Guidelines for the Continuous Supervision of Listed Companies No. 8 - Share Reduction and Shareholding Management", which was released and implemented on December 30, 2022.
In other words, starting from tomorrow, the company's directors, supervisors and senior executives will not be as free as before to reduce their shareholdings. This is specifically reflected in the following aspects: First, the pre-disclosure requirements for the transfer of holdings through bulk transactions and agreements are clarified. The second is to clarify the criteria for judging the source of shares. The third is to clarify the connection between the requirements for shareholding reduction and the two financing businesses. I won’t go into the specific rules. You can check the news yourself. In short, the Beijing Stock Exchange has stricter management of shareholders of listed companies reducing their holdings of stocks . This also protects the interests of small and medium-sized investors from being harmed.
Although this set of rules only applies to North Exchange stocks, I think this is just a pilot. If the effect is good, it may be applied to the entire market. Some stocks themselves are not doing well, and if major shareholders reduce their holdings illegally, it will make things worse, which will cause too much harm to retail investors.
News 3: Sinopharm Holdings announced on November 2 that the company’s controlling shareholder China Pharmaceutical Group Co., Ltd. has entered into an agreement with Merck & Co. html in September 2022. 2 signed a cooperation framework agreement and was granted the distribution rights and exclusive import rights in mainland China for the anti-COVID-19 oral drug monogravir capsules (trade name: LAGEVRIO) (monoravir) jointly developed by Merck and Ridgeback Biotechnology.
As soon as China's epidemic situation was relaxed, foreign drugs poured in in large quantities. From the perspective of capital, everyone wants a piece of China's cake, but from the perspective of us ordinary people, are these drugs really what we need? Seriously, if these drugs were really effective, would there still be so many deaths in the United States? However, judging from the recent rush for medicine, it is obvious that ordinary people are a little sick and are rushing to seek medical treatment. When this medicine is introduced, there will definitely be people snatching it.In terms of
stocks, China Pharmaceuticals , as an agent, will definitely have a double harvest in terms of revenue and net profit. Next, let’s look at its stock price performance. If it falls again, it will be a bit embarrassing.
Market outlook
The Chinese stock market has been on a truce for three days and has rested. Apart from the epidemic, there is no other bad news during this holiday. Tomorrow is the first game of 2023. I think getting a good start is of great significance, and it is not difficult for the main force. Focus on three sectors, one is big finance, which is the market leader; the other is new energy, which will have the motivation to rise after full adjustment; the last one is the big medical sector, whether it can regain its glory and make the market positive depends on its performance.
